lansoprazole has been researched along with Osteoporotic Fractures in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Osteoporotic Fractures: Breaks in bones resulting from low bone mass and microarchitectural deterioration characteristic of OSTEOPOROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although based on observational studies, there is substantial evidence associating the long-term use of PPIs and fracture." | 2.82 | Proton Pump Inhibitors and Bone Health: An Update Narrative Review. ( Lespessailles, E; Toumi, H, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lespessailles, E | 1 |
| Toumi, H | 1 |
1 review available for lansoprazole and Osteoporotic Fractures
| Article | Year |
|---|---|
Proton Pump Inhibitors and Bone Health: An Update Narrative Review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Antacids; Bone Density; Dexlanso | 2022 |